EA200100165A1 - Применение усилителя захвата глюкозы для уменьшения апоптоза - Google Patents

Применение усилителя захвата глюкозы для уменьшения апоптоза

Info

Publication number
EA200100165A1
EA200100165A1 EA200100165A EA200100165A EA200100165A1 EA 200100165 A1 EA200100165 A1 EA 200100165A1 EA 200100165 A EA200100165 A EA 200100165A EA 200100165 A EA200100165 A EA 200100165A EA 200100165 A1 EA200100165 A1 EA 200100165A1
Authority
EA
Eurasian Patent Office
Prior art keywords
application
cells
reduce apoptosis
human
capture amplifier
Prior art date
Application number
EA200100165A
Other languages
English (en)
Russian (ru)
Inventor
Антуан Мишель Алан Бриль
Робин Эдвин Бакингэм
Нассира Кандуди
Original Assignee
Смитклайн Бичам Плс
Смитклайн Бичам Лаборатуар Фармасетик
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9815871.0A external-priority patent/GB9815871D0/en
Priority claimed from GBGB9815872.8A external-priority patent/GB9815872D0/en
Priority claimed from GBGB9905387.8A external-priority patent/GB9905387D0/en
Application filed by Смитклайн Бичам Плс, Смитклайн Бичам Лаборатуар Фармасетик filed Critical Смитклайн Бичам Плс
Publication of EA200100165A1 publication Critical patent/EA200100165A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EA200100165A 1998-07-21 1999-07-21 Применение усилителя захвата глюкозы для уменьшения апоптоза EA200100165A1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9815871.0A GB9815871D0 (en) 1998-07-21 1998-07-21 Novel compound
GBGB9815872.8A GB9815872D0 (en) 1998-07-21 1998-07-21 Novel method
GBGB9905387.8A GB9905387D0 (en) 1999-03-09 1999-03-09 Novel method
PCT/GB1999/002361 WO2000004890A1 (en) 1998-07-21 1999-07-21 Use of glucose uptake enhancer for reducing apoptosis

Publications (1)

Publication Number Publication Date
EA200100165A1 true EA200100165A1 (ru) 2001-08-27

Family

ID=27269407

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200100165A EA200100165A1 (ru) 1998-07-21 1999-07-21 Применение усилителя захвата глюкозы для уменьшения апоптоза

Country Status (25)

Country Link
EP (2) EP1516617A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2002521326A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR20010079551A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1310620A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AP (1) AP2001002036A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE288746T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU5053799A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BG (1) BG105250A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR9912117A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2338211A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69923687T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK1098639T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA200100165A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2237929T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUP0103199A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ID (1) ID26986A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL140664A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO20010292L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
OA (1) OA11579A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL345627A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT1098639E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI1098639T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK1012001A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TR (1) TR200100207T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2000004890A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3073600A (en) * 1999-01-19 2000-08-07 Sankyo Company Limited Inhibitor for nerve cell death due to glutamic acid cytotoxicity
ES2204684T3 (es) * 1999-08-27 2004-05-01 Eli Lilly And Company Derivados de biaril-oxa(tia)zol y su uso como modulares de ppar.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2137915T3 (es) * 1987-09-04 2000-01-01 Beecham Group Plc Derivados de tiazolidindiona sustituida.
JPH05202042A (ja) * 1992-01-24 1993-08-10 Sankyo Co Ltd 糖尿病性合併症治療剤
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
NZ314406A (en) * 1996-03-18 2000-12-22 Sankyo Co Treatment or prophylaxis of pancreatitis with a medicament containing an insulin sensitiser including oxazoles and thiazoles
GB9611947D0 (en) * 1996-06-07 1996-08-07 Glaxo Group Ltd Medicaments
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
WO1998010760A1 (fr) * 1996-09-12 1998-03-19 Sankyo Company, Limited Potentialisateur d'activite de glutathione-reductase contenant de la troglitazone
GB9721692D0 (en) * 1997-10-13 1997-12-10 Smithkline Beecham Plc Novel treatment
ATE325607T1 (de) * 1997-11-19 2006-06-15 Takeda Pharmaceutical Aptoptoseinhibitoren
AU2781899A (en) * 1998-02-24 1999-09-15 Trustees Of The University Of Pennsylvania, The Use of a cardiac purinoceptor to effect cellular glucose uptake
AU4005299A (en) * 1998-05-19 1999-12-06 Regents Of The University Of California, The Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis
US5968960A (en) * 1999-01-14 1999-10-19 The Regents Of The University Of California Use of thiazolidinediones to ameliorate the adverse consequences of myocardial ischemia on myocardial function and metabolism

Also Published As

Publication number Publication date
EP1516617A2 (en) 2005-03-23
TR200100207T2 (tr) 2001-05-21
HUP0103199A2 (hu) 2002-05-29
DE69923687D1 (de) 2005-03-17
NO20010292D0 (no) 2001-01-18
BR9912117A (pt) 2001-04-10
NO20010292L (no) 2001-03-08
SK1012001A3 (en) 2001-08-06
DE69923687T2 (de) 2006-04-06
ID26986A (id) 2001-02-22
PT1098639E (pt) 2005-06-30
EP1098639B1 (en) 2005-02-09
BG105250A (en) 2001-11-30
AU5053799A (en) 2000-02-14
ES2237929T3 (es) 2005-08-01
AP2001002036A0 (en) 2001-03-31
SI1098639T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2005-08-31
ATE288746T1 (de) 2005-02-15
EP1098639A1 (en) 2001-05-16
OA11579A (en) 2004-06-01
PL345627A1 (en) 2002-01-02
DK1098639T3 (da) 2005-06-13
IL140664A0 (en) 2002-02-10
CN1310620A (zh) 2001-08-29
CA2338211A1 (en) 2000-02-03
JP2002521326A (ja) 2002-07-16
WO2000004890A1 (en) 2000-02-03
HK1037865A1 (en) 2002-02-22
HUP0103199A3 (en) 2002-08-28
KR20010079551A (ko) 2001-08-22

Similar Documents

Publication Publication Date Title
PT1017692E (pt) 4-heteroaril-tetrahidroquinolinas e sua aplicacao como inibidores da proteina de transferencia de ester de colesterol (ctep)
DK1066052T3 (da) Mesenchymstamceller til forebyggelse og behandling af immunreaktioner ved transplantationer
EA199800626A1 (ru) Применение агониста ppar-гамма для лечения синдрома х
EA199901027A1 (ru) Сложные моноэфиры пробукола для лечения сердечно-сосудистых и воспалительных заболеваний
TR199700358A2 (xx) �nterferon birle�imler.
EA200101089A1 (ru) Новый способ лечения
ATE71298T1 (de) Immunoregulation.
EE9800387A (et) Implantatsiooni tõhustamine pärast in vitro viljastamist
ATE255632T1 (de) Immortalisierung bzw. desimmortalisierung von zellen
PT888271E (pt) Derivados de benzamidina substituidos com derivados de aminoacidos e hidroxiacidos e sua utilizacao como anticoagulantes
IT1175868B (it) Amplificatore con conversione corrente-tensione, in particolare preamplificatore di ricevitore ottico
FI950436A0 (fi) Glykogeenipolysakkaridit
DE69010482D1 (de) Unterhose.
ES2058343T3 (es) Piridinas disubstituidas.
EA200100165A1 (ru) Применение усилителя захвата глюкозы для уменьшения апоптоза
NO890356D0 (no) Fremgangsmaate til aa utfoere vei- og markkonstruksjoner.
EP0410295A3 (en) Single-ended chopper stabilized operational amplifier
FI880636L (fi) Foerfarande foer inaktivering av med hoelje foersedda virus i en medelst en cell in vitro framstaellda proteinprodukter.
EA199900579A1 (ru) Применение ингибиторов комт для производства лекарственного средства для профилактики сосудистых дисфункций при диабете
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
BR9915767A (pt) Artigo absorvente dotado de um canal
EA200100164A1 (ru) Применение усилителя захвата глюкозы для уменьшения постишемического повреждения сердца
ATE329600T1 (de) Verwendung von tagatose zur verbesserung wichtiger blutfaktoren
SE9803398D0 (sv) "New use"
DE3853380D1 (de) Physiologisch aktives Lymphotoxin.